{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:29Z","timestamp":1792946069134,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jacadv.2026.103388","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:00:04Z","timestamp":1792789204000},"page":"103388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Finerenone-Empagliflozin Combination Therapy in Apparent Resistant Hypertension"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Mottl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacadv.2026.103388_bib1","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"10003","key":"10.1016\/j.jacadv.2026.103388_bib2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103388_bib3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"issue":"24","key":"10.1016\/j.jacadv.2026.103388_bib4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","article-title":"Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients","volume":"61","author":"De Nicola","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103388_bib5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103388_bib6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103388_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey","year":"2022","journal-title":"JAMA"},{"issue":"10008","key":"10.1016\/j.jacadv.2026.103388_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"10208","key":"10.1016\/j.jacadv.2026.103388_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103388_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"10367","key":"10.1016\/j.jacadv.2026.103388_bib11","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103388_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000492622","article-title":"Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study","volume":"48","author":"Agarwal","year":"2018","journal-title":"Am J Nephrol"},{"issue":"10304","key":"10.1016\/j.jacadv.2026.103388_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103388_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103388_bib15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2215\/CJN.04110422","article-title":"Prevalence of apparent treatment-resistant hypertension in chronic kidney disease in two large US health care systems","volume":"17","author":"An","year":"2022","journal-title":"CJASN"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103388_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/HYPERTENSIONAHA.120.15064","article-title":"Adverse health outcomes associated with refractory and treatment resistant hypertension in the Chronic Renal Insufficiency Cohort (CRIC)","volume":"77","author":"Buhnerkempe","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103388_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103388_bib18","doi-asserted-by":"crossref","first-page":"F729","DOI":"10.1152\/ajprenal.00407.2020","article-title":"Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms","volume":"319","author":"Bovee","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103388_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103388_bib20","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacadv.2026.103388_bib21","article-title":"CD8(+) T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103388_bib22","doi-asserted-by":"crossref","first-page":"R1136","DOI":"10.1152\/ajpregu.00298.2009","article-title":"T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats","volume":"298","author":"De Miguel","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103388_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103388_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103388_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103388_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103388_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103388_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-023-01281-1","article-title":"Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations","volume":"25","author":"Beal","year":"2023","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103388_bib29","doi-asserted-by":"crossref","first-page":"F32","DOI":"10.1152\/ajprenal.00119.2025","article-title":"Gliflozins in hypertension: basic mechanisms and clinical insights","volume":"329","author":"Rieg","year":"2025","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103388_bib30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.jacadv.2026.103388_bib31","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103388_bib32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","article-title":"Risk of hyperkalemia with empagliflozin, finerenone, or both","volume":"87","author":"Agarwal","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacadv.2026.103388_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in Chronic Kidney Disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.jacadv.2026.103388_bib34","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in Diabetes\u20142026","volume":"49","author":"American Diabetes Association Professional Practice Committee for D","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2026.103388_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.126.27036","article-title":"Safety and synergy of finerenone and empagliflozin in lowering blood pressure","author":"Agarwal","year":"2026","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103388_bib36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103388_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11906-020-01081-x","article-title":"Resistant hypertension in Chronic Kidney Disease (CKD): prevalence, treatment particularities, and research agenda","volume":"22","author":"Georgianos","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"16","key":"10.1016\/j.jacadv.2026.103388_bib38","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/jama.2026.1221","article-title":"Diagnosis and management of resistant hypertension: a review","volume":"335","author":"Azizi","year":"2026","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103388_bib39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.ki.5000177","article-title":"Hypertension in renal parenchymal disease: why is it so resistant to treatment?","volume":"69","author":"Campese","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103388_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41440-018-0122-5","article-title":"Changing views on the common physiologic abnormality that mediates salt sensitivity and initiation of salt-induced hypertension","volume":"42","author":"Kurtz","year":"2019","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103388_bib41","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103388_bib42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103388_bib43","series-title":"JARDIANCE (empagliflozin tablets), for oral use. Prescribing information","year":"2025"},{"key":"10.1016\/j.jacadv.2026.103388_bib44","article-title":"KERENDIA (finerenone) tablets, for oral use","year":"2025","journal-title":"Prescribing information"},{"issue":"Suppl 2","key":"10.1016\/j.jacadv.2026.103388_bib45","doi-asserted-by":"crossref","first-page":"ii10","DOI":"10.1093\/ckj\/sfaf285","article-title":"2025 update on resistant hypertension in CKD: where do we stand and where do we go?","volume":"18","author":"Schmieder","year":"2025","journal-title":"Clin Kidney J"},{"issue":"10532","key":"10.1016\/j.jacadv.2026.103388_bib46","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103388_bib47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.060167","article-title":"Chlorthalidone for resistant hypertension in advanced chronic kidney disease","volume":"146","author":"Agarwal","year":"2022","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.jacadv.2026.103388_bib48","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jacadv.2026.103388_bib49","first-page":"1304","article-title":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","volume":"46","author":"Bohm","year":"2025","journal-title":"Eur Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26008100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26008100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:50:04Z","timestamp":1792943404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26008100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2772963X26008100"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103388","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone-Empagliflozin Combination Therapy in Apparent Resistant Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103388"}}